MediPost-OmniaBio Discuss Collaboration Plans for CDMO Business

Mitchell Zibilotti, CEO of Omniabio, Visits Korea
Holds 40% Stake in Medipost... Becomes Largest Shareholder in 27 Years

The OmniaBio delegation, who visited Korea to discuss cooperation plans related to the CDMO business, is taking a commemorative photo at the Medipost headquarters. (Photo by Medipost)

[Asia Economy Reporter Chunhee Lee] Medipost announced on the 1st that its affiliate, OmniaBio, a specialized company in cell and gene therapy (CGT) contract development and manufacturing organization (CDMO), visited Korea to discuss cooperation plans related to the CDMO business. The visit included Mitchel Sivilotti, CEO of OmniaBio, and Michael May, CEO of CCRM, OmniaBio's parent company.

In May, Medipost decided to invest a total of 90 million Canadian dollars (approximately 87.2 billion KRW) in OmniaBio, Canada, through the acquisition of existing shares and convertible bonds to newly enter the North American CDMO business. Through this, Medipost currently holds 39.6% of OmniaBio's shares, and after the convertible bonds convert to common stock in 2027, Medipost is expected to become the largest shareholder of OmniaBio.

This visit took place over two days from the 30th of last month to the 1st, including a visit to the CDMO facilities within Medipost's GMP factory and the 'Cartistem' production site, as well as meetings with domestic CDMO clients.

OmniaBio directly visited the CDMO site within Medipost's Guro GMP factory to tour the CGT contract manufacturing facilities and research personnel. The two companies discussed strategic CDMO business cooperation plans connecting North America and East Asia. OmniaBio agreed to actively share know-how such as process development (PD) capabilities and quality management systems.

Mitchel Sivilotti, CEO of OmniaBio, said, "This visit was a great opportunity to directly confirm the excellence of Medipost's CDMO facilities and personnel," adding, "We expect to serve as a bridgehead for OmniaBio's entry into Asia."

A Medipost official stated, "OmniaBio, which has long operated a CDMO business applying global standards, has agreed to actively cooperate with our domestic CDMO business entry," and added, "By combining Medipost's cell therapy development and production capabilities with OmniaBio's differentiated PD and production know-how and quality management systems, we plan to provide a one-stop total solution supporting the entire new drug development process."

This content was produced with the assistance of AI translation services.